Monday, October 27, 2025

Pfizer To Acquire Clinical-Stage Biotech Firm Arena Therapeutics For US$6.7 Billion

Pfizer Inc. (NYSE: PFE) announced on Monday the definitive agreement to acquire clinical stage biopharmaceutical firm Arena Therapeutics (Nasdaq: ARNA). The transaction is reportedly valued at approximately US$6.7 billion.

Under the terms of the agreement, Pfizer will acquire all Arena’s outstanding shares at US$100.00 per share.

“The proposed acquisition of Arena complements our capabilities and expertise in Inflammation and Immunology,” said Global President & General Manager Mike Gladstone. “Utilizing Pfizer’s leading research and global development capabilities, we plan to accelerate the clinical development of etrasimod for patients with immuno-inflammatory diseases.”

Arena’s portfolio, currently all in clinical trials or exploratory stages, includes drug candidates meant to treat a host of diseases in gastroenterology, dermatology, and cardiovascular–like ulcerative colitis, atopic dermatitis, and acute heart failure.

In particular, the biotech firm’s drug candidate olorinab is an investigational full agonist of the cannabinoid type 2 receptor initially being explored to treat visceral pain associated with gastrointestinal disorders. 

The transaction is expected to be funded by Pfizer’s cash on hand.

Pfizer last traded at US$61.25 on the NYSE while Arena Therapeutics last traded at US$92.21 on the Nasdaq.


Information for this briefing was found via the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

The Best News for Gold Was the Drop! – Peter Grandich

McEwen Copper: The Los Azules Feasibility Study

This Is Why the Gold Run Is Not Done! | Peter Marrone – Allied Gold

Recommended

Steadright Enters MOU To Acquire Historic Goundafa Polymetallic Mine In Morocco

Military Seizes Power in Madagascar After President Flees

Related News

Pfizer-BioNTech COVID-19 Vaccine Trial For Ages 5-11 Returns Favorable Topline Results

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced this morning the topline results...

Monday, September 20, 2021, 09:17:00 AM

New COVID Variant Sweeps China, Is North America Next?

Remarkably, the world could be facing another bout with COVID this year, and with negative...

Thursday, May 25, 2023, 07:35:00 AM

BioNTech Sent Plummeting Following Damning Whistleblower Report, News of Covid-19 Pills

Shares of BioNTech (NASDAQ: BNTX) were sent into a nosedive on Friday, after a whistleblower...

Sunday, November 7, 2021, 01:19:00 PM

Pfizer-BioNTech Set To Supply The US Government With 105 Million COVID-19 Vaccine For US$3.2 Billion

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced on Wednesday a new vaccine...

Thursday, June 30, 2022, 02:19:00 PM

Well Health, Bombardier To Be Added To S&P/TSX Composite Index

The latest changes for the S&P/TSX Composite Index, assembled by S&P Down Jones Indices, were...

Sunday, September 5, 2021, 12:09:00 PM